Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Joerg Hoffmann
Observed names:
Hoffmann, Joerg,
J Hoffmann,
J. Hoffmann,
J.C. Hoffmann,
Joerg C. Hoffmann,
Joerg Christian Hoffmann,
Jörg Hoffmann
show all 7
Institutions:
Philipps University of Marburg,
Universitätsklinikum Gießen und Marburg
Observed institutions:
University of Bern,
Philipps University of Marburg,
Universitätsklinikum Gießen und Marburg,
Robert Bosch Hospital,
Medizinische Hochschule Hannover,
Universitätsklinikum des Saarlandes,
University of Bologna
show all 7
ORCID:
0000-0003-2820-1501
Observed ORCID:
0000-0003-2820-1501
OpenAlex ID:
A5103188384
Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients
2007
·
Tanja Spoettl
, Martin Hausmann
, et al.
·
Inflammatory Bowel Diseases
·
88
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
2015
·
A Burchert
, S Saussele
, et al.
·
Leukemia
·
66
Diagnostics and Treatment of Crohn's Disease
2003
·
E F Stange
, S Schreiber
, et al.
·
Zeitschrift für Gastroenterologie
·
58
Determination of CD43 and CD200 surface expression improves accuracy of B‐cell lymphoma immunophenotyping
2020
·
Joerg Hoffmann
, Marissa Rother
, et al.
·
Cytometry Part B Clinical Cytometry
·
32
PDF
Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis
2013
·
Joerg Christian Hoffmann
, Kathleen Stabla
, et al.
·
Annals of Hematology
·
27
Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method
2022
·
Joerg Hoffmann
, Michael C. Thrun
, et al.
·
Cytometry Part A
·
21
PDF
Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia
2023
·
Joerg Hoffmann
, Semil Eminovic
, et al.
·
Current Oncology
·
20
PDF
Development of an explainable AI system using routine clinical parameters for rapid differentiation of inflammatory conditions
2024
·
Joerg Hoffmann
, Anne Rheude
, et al.
·
Frontiers in Immunology
·
8
PDF
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
2022
·
Roch Houot
, Viola Poeschel
, et al.
·
HemaSphere
·
6
The Low Expression of Fc-Gamma Receptor III (CD16) and High Expression of Fc-Gamma Receptor I (CD64) on Neutrophil Granulocytes Mark Severe COVID-19 Pneumonia
2022
·
Joerg Hoffmann
, Rojin Etati
, et al.
·
Diagnostics
·
5
PDF
Rituximab induces a flare-up of activated neutrophil extracellular traps under in vitro conditions
2022
·
Joerg Hoffmann
, Samira Roesner
, et al.
·
Immunopharmacology and Immunotoxicology
·
5
Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case report
2023
·
Joerg Hoffmann
, Georg Schliesser
, et al.
·
Hematology
·
4
PDF
Classifying with the Fine Structure of Distributions: Leveraging Distributional Information for Robust and Plausible Naïve Bayes
2026
·
Quirin Stier
, Jörg Hoffmann
, et al.
·
Machine Learning and Knowledge Extraction
·
2
PDF
S1694 Human Peripheral γδ T Cells Possess Regulatory Potential
2009
·
Anja A. Kuehl
, Christoph Loddenkemper
, et al.
·
Gastroenterology
·
2
PDF
Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feasibility, efficacy and molecular predictors
2023
·
S. Denker
, A. Bittner
, et al.
·
Hematological Oncology
PDF
Peripheral T‐cell lymphoma immunophenotype in a patient with a history of Muromonab‐CD3 therapy: A case report and a diagnostic dilemma
2021
·
Joerg Hoffmann
, Andreas Klameth
, et al.
·
Cytometry Part B Clinical Cytometry
Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma
2020
·
Lorenz Thurner
, Viola Poeschel
, et al.
·
Blood
Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial
2020
·
Roch Houot
, Viola Poeschel
, et al.
·
Blood
Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx
2020
·
Lorenz Thurner
, Viola Poeschel
, et al.
·
HAL
Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma
2019
·
Gerhard Held
, Corinne Haioun
, et al.
·
Blood
Stenosedilatation bei Morbus Crohn
2013
·
F. Freyburger
, G. Arling
, et al.
·
Verdauungskrankheiten
Targeting Human CD2 by the CB.219 Monoclonal Antibody Protects From Intestinal Inflammation in a Humanized Colitis Model
2011
·
Anja A. Kuehl
, Nina N. Pawlowski
, et al.
·
Gastroenterology
T1208 Anti-Human CD2 MAb Treatment Protects from Colitis in a Humanized Animal Model
2008
·
Anja A. Kuehl
, Christoph Loddenkemper
, et al.
·
Gastroenterology
PDF
Hematopoietic Stem Cells Actively Extrude Imatinib-Mesylate Due to High ABCG2-Transporter Activity.
2005
·
Christian Scharenberg
, Michaela Gessner
, et al.
·
Blood
Aldehyde Dehydrogenase Expression in Primitive Human Hematopoietic Progenitor Cells with Side Population Characteristic and in Samples from Patients with Acute Myeloid Leukemia.
2005
·
Ute Meissauer
, Joerg Hoffmann
, et al.
·
Blood
Show more works
View as search
Works count:
34
Citation count:
344
H-index:
8
I10-index:
7
Year
Topic
Type